Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc
ERBB家族成员作为骨肉瘤治疗靶点的临床前评估
基本信息
- 批准号:8628786
- 负责人:
- 金额:$ 33.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2016-02-29
- 项目状态:已结题
- 来源:
- 关键词:AdolescentAdolescent and Young AdultAffectAntigensApoptosisBehaviorBindingBiologyCategoriesCell LineCell NucleusCell ProliferationCellsCessation of lifeCharacteristicsChildClinicalClinical TrialsDataDevelopmentDevelopmental Therapeutics ProgramDiagnosisDiseaseDisease modelDrug usageEGFR geneEGFR inhibitionERBB2 geneEmployee StrikesEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEvaluationEventFamilyFamily memberGenesGoalsGrowthImmunohistochemistryIn VitroIndividualKnowledgeLaboratoriesLeftMalignant - descriptorMalignant Bone NeoplasmMalignant Childhood NeoplasmMalignant NeoplasmsMalignant neoplasm of lungMedicineModelingMolecularMolecular MedicineNeoplasm MetastasisNuclearNuclear TranslocationOperative Surgical ProceduresOrthodonticOutcomePathogenesisPathologyPatientsPharmacologic SubstancePhasePhenotypePhosphorylationPlayPrognostic MarkerProtein Array AnalysisProtein IsoformsRare DiseasesReceptor Protein-Tyrosine KinasesRoleSamplingSignal TransductionSolid NeoplasmSpecimenStaining methodStainsTechniquesTherapeuticUnited StatesXenograft Modeladvanced diseasebasebonechemotherapyclinically relevantdefined contributiondisabilityimprovedin vivoinhibitor/antagonistinterestmalignant breast neoplasmmembernovelosteosarcomapre-clinicalpreclinical evaluationprognosticpromoterreceptorsmall moleculetherapeutic evaluationtherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone cancer, and the third most common solid tumor in adolescents, affecting nearly 1000 people per year in the United States. This disease desperately needs new therapies, since nearly 40% of those diagnosed will die of their disease, and the survival for this disease has not truly improved in more than 25 years. Signals from the ERBB family of receptor tyrosine kinases contribute essential signals to osteosarcoma, and that a pan-ERBB inhibitor is more effective at stopping the growth of osteosarcoma than is a selective EGFR inhibitor or an inhibitor that blocks signals from either EGFR or Her-2. Most osteosarcoma is do express EGFR, and that those which express Her-2 have a greater propensity to metastasize. However, the specific contributions of Her-2 and Her-4 to malignant behavior in osteosarcoma are largely undocumented. Of the four ERBB family members, Her-4 is the least well characterized. Based upon the in vitro superiority of pan ERBB inhibition compared to inhibition of EGFR and Her-2 alone, it is hypothesized that Her-4 makes unique contributions to osteosarcoma pathology. Likewise, since Her-2 is associated with a more metastatic phenotype, it is likely that it also has unique contributions. This proposal is intended to evaluate the scientific basis for therapies targeting the ERBB family of receptor tyrosine kinases for treating osteosarcoma, by defining the unique contributions of each of the family members within this disease. In the first specific aim, molecular approaches are used to evaluate the precise contributions of each ERBB family member to osteosarcoma biology, focusing particularly on the role of Her-4 in the nucleus and its potential to regulate the expression of other genes. In the second specific aim, a large bank of archival osteosarcoma specimens is evaluated for expression of members of the ERBB family, correlating expression with clinical outcome. In the third specific aim, to novel orthodontic osteosarcoma xenograft models are used to evaluate the therapeutic potential of a specific pan ERBB inhibitor, PF00299804. The effect of eliminating individual ERBB family members also is evaluated. When successfully completed, the proposed studies will define the specific contributions of each ERBB family member to osteosarcoma biology, understanding their role in a clinical context, and potentially providing the basis for using a pan ERBB inhibitor for treating patients with osteosarcoma. Should the underlying hypothesis be proven, these studies would pave the way for new clinical trials for children who desperately need new treatments.
描述(由申请人提供):骨肉瘤是最常见的原发性骨癌,也是青少年中第三大常见的实体瘤,在美国每年影响近 1000 人。这种疾病迫切需要新的治疗方法,因为近 40% 的确诊患者将死于这种疾病,而且这种疾病的生存率在 25 年多的时间里并没有真正改善。来自受体酪氨酸激酶 ERBB 家族的信号为骨肉瘤提供重要信号,并且泛 ERBB 抑制剂在阻止骨肉瘤生长方面比选择性 EGFR 抑制剂或阻断 EGFR 或 Her-2 信号的抑制剂更有效。大多数骨肉瘤确实表达 EGFR,并且表达 Her-2 的骨肉瘤具有更大的转移倾向。然而,Her-2 和 Her-4 对骨肉瘤恶性行为的具体贡献很大程度上没有记录。在四个 ERBB 家族成员中,Her-4 的特征最不明确。基于与单独抑制 EGFR 和 Her-2 相比,全 ERBB 抑制的体外优越性,假设 Her-4 对骨肉瘤病理学做出独特的贡献。同样,由于 Her-2 与更具转移性的表型相关,因此它很可能也具有独特的贡献。该提案旨在通过定义每个家族成员对该疾病的独特贡献,评估针对 ERBB 受体酪氨酸激酶家族治疗骨肉瘤的疗法的科学基础。在第一个具体目标中,使用分子方法评估每个 ERBB 家族成员对骨肉瘤生物学的精确贡献,特别关注 Her-4 在细胞核中的作用及其调节其他基因表达的潜力。在第二个具体目标中,评估大量档案骨肉瘤标本中 ERBB 家族成员的表达,将表达与临床结果相关联。第三个具体目标是使用新型正畸骨肉瘤异种移植模型来评估特定泛 ERBB 抑制剂 PF00299804 的治疗潜力。还评估了消除个别 ERBB 家庭成员的效果。成功完成后,拟议的研究将确定每个 ERBB 家族成员对骨肉瘤生物学的具体贡献,了解它们在临床背景中的作用,并可能为使用泛 ERBB 抑制剂治疗骨肉瘤患者提供基础。如果基本假设得到证实,这些研究将为迫切需要新治疗的儿童进行新的临床试验铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eugenie S Kleinerman其他文献
Eugenie S Kleinerman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eugenie S Kleinerman', 18)}}的其他基金
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc
ERBB家族成员作为骨肉瘤治疗靶点的临床前评估
- 批准号:
8795278 - 财政年份:2010
- 资助金额:
$ 33.93万 - 项目类别:
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc
ERBB家族成员作为骨肉瘤治疗靶点的临床前评估
- 批准号:
9040524 - 财政年份:2010
- 资助金额:
$ 33.93万 - 项目类别:
VACDXR WITH OR WITHOUT IMMTHER FOR NEWLY DIAGNOSED HIGH RISK EWING'S SARCOMA
VACDXR 联合或不联合 IMMTHER 用于新诊断的高风险尤文氏肉瘤
- 批准号:
7204609 - 财政年份:2005
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: useintherapy
尤文氏肉瘤的血管发生:在治疗中的应用
- 批准号:
7079330 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
尤文肉瘤的血管发生:对治疗的影响
- 批准号:
7911885 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
尤文肉瘤的血管发生:对治疗的影响
- 批准号:
7368263 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: useintherapy
尤文氏肉瘤的血管发生:在治疗中的应用
- 批准号:
6914939 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
尤文肉瘤的血管发生:对治疗的影响
- 批准号:
8302422 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
尤文肉瘤的血管发生:对治疗的影响
- 批准号:
7684680 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
Vasculogenesis in Ewing's Sarcoma: Implications for Ther
尤因肉瘤的血管发生:对治疗的影响
- 批准号:
6819783 - 财政年份:2004
- 资助金额:
$ 33.93万 - 项目类别:
相似海外基金
Social media as a social mechanism of non-cigarette tobacco use: Engaging young adults to examine tobacco culture online
社交媒体作为非卷烟烟草使用的社会机制:让年轻人在线审视烟草文化
- 批准号:
10667700 - 财政年份:2023
- 资助金额:
$ 33.93万 - 项目类别:
Development of an online, theory-based intervention to reduce e-cigarette use and susceptibility to smoking in young adults: A pilot study
开发基于理论的在线干预措施,以减少年轻人的电子烟使用和吸烟易感性:一项试点研究
- 批准号:
10664232 - 财政年份:2023
- 资助金额:
$ 33.93万 - 项目类别:
Chronic GVHD and Management of its Sequelae
慢性 GVHD 及其后遗症的处理
- 批准号:
10679975 - 财政年份:2023
- 资助金额:
$ 33.93万 - 项目类别:
The effects of flavored e-cigarette sales bans on tobacco-use behaviors among youth and adults
调味电子烟销售禁令对青少年和成年人烟草使用行为的影响
- 批准号:
10805935 - 财政年份:2023
- 资助金额:
$ 33.93万 - 项目类别: